Over the past two decades, the idea of targeting transcription factors to combat malignancies has turned into a clinical reality.

A recent study led by Associate Professor Takuya Yamamoto and Researcher May Nakajima-Koyama has revealed that maintaining a ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Published in Cell Reports Medicine, results of a VHIO-led study support the feasibility of using RAD51 testing to complement ...

A recent study led by Associate Professor Takuya Yamamoto and Researcher May Nakajima-Koyama has revealed that maintaining a delicate balance between interferon-gamma (IFN-γ) and extracellular ...

The MYC family of proteins ... As a key survival signaling pathway, the MDM2/p53 axis is widely involved in the development of many tumors. Preclinical and clinical trials provide evidence ...

Published in Cell Reports Medicine, results of a VHIO-led study support the feasibility of using RAD51 testing to complement next-generation ...

A number of signaling pathways have been shown to be central to myeloma growth and survival including NFκB, MAPK, PI3K, JAK/STAT, MYC, MAF and the UPR. Molecules inhibiting these pathways have ...

and four molecular subtypes with significant phenotypic and clinical differences induced by different oncogenic signaling pathways were identified: TGF-β+ subtype; cell cycle, MYC, and NF2− subtype; ...